Clinical Trial Update: A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis [Phase 2, Phase 3]

View source ↗

Summary

This Phase 2/3 open-label extension study evaluated the long-term safety and efficacy of VX-509 in rheumatoid arthritis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VX-509

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2, Phase 3 | Status: COMPLETED